He voted that year to add Wyeth-Ayerst Pharmaceuticals’s rotavirus vaccine, RotaShield, to the mandatory schedule despite the absence of functional safety studies. Offit knew that ACIP’s positive vote on Wyeth’s rotavirus jab would virtually guarantee a similar approval for his own rotavirus vaccine during an upcoming ACIP session.
